Ask AI
Thrombosis in ET and PV

CME

High Suspicion, Better Outcomes: Evaluating Thrombotic Events for Underlying ET or PV

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: May 14, 2026

Expiration: November 13, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Pankit Vachhani, MD, discusses the multifactorial pathogenesis, risk assessment, clinical impact, and management strategies of thrombotic events in myeloproliferative neoplasms (MPNs), including the role of hematologic abnormalities, JAK2 mutations, and evidence-based treatment approaches.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with essential thrombocythemia (ET) or polycythemia vera (PV) do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting:

Which of the following cases of thrombosis should raise a suspicion of an MPN as the underlying cause in a patient previously undiagnosed with an MPN?